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Crystal structures of reduced, oxidized, and mutated human
thioredoxins: evidence for a regulatory homodimer
Andrzej Weichsel1, John R Gasdaska2, Garth Powis2 and William R Montfort1*
Background:  Human thioredoxin reduces the disulfide bonds of numerous
proteins in vitro, and can activate transcription factors such as NFkB in vivo.
Thioredoxin can also act as a growth factor, and is overexpressed and secreted
in certain tumor cells. 
Results:  Crystal structures were determined for reduced and oxidized wild type
human thioredoxin (at 1.7 and 2.1 Å nominal resolution, respectively), and for
reduced mutant proteins Cys73→Ser and Cys32→Ser/Cys35→Ser (at 1.65 and
1.8 Å, respectively). Surprisingly, thioredoxin is dimeric in all four structures; the
dimer is linked through a disulfide bond between Cys73 of each monomer, except
in Cys73→Ser where a hydrogen bond occurs. The thioredoxin active site is
blocked by dimer formation. Conformational changes in the active site and dimer
interface accompany oxidation of the active-site cysteines, Cys32 and Cys35.
Conclusions:  It has been suggested that a reduced pKa in the first cysteine
(Cys32 in human thioredoxin) of the active-site sequence is important for
modulation of the redox potential in thioredoxin. A hydrogen bond between the
sulfhydryls of Cys32 and Cys35 may reduce the pKa of Cys32 and this pKa
depression probably results in increased nucleophilicity of the Cys32 thiolate
group. This nucleophilicity, in turn, is thought to be necessary for the role of
thioredoxin in disulfide-bond reduction. The physiological role, if any, of thioredoxin
dimer formation remains unknown. It is possible that dimerization may provide a
mechanism for regulation of the protein, or a means of sensing oxidative stress. 
Introduction
Thioredoxin is a small (~12 kDa) protein found in all
living cells. The protein uses the conserved sequence
Trp–Cys–Gly–Pro–Cys to either reduce disulfide bonds or
oxidize sulfhydryls in a variety of proteins, both intracellu-
larly and extracellularly. The first characterized role for
the protein was as part of a system that shuttles hydrogen
from NADPH, through thioredoxin reductase and thio-
redoxin, to the oxidized form of the essential enzyme
ribonucleotide reductase, resulting in a reduced disulfide
bond in this latter reductase (reviewed in [1–3]). During
this sequence, cysteines in the thioredoxin active site
undergo both disulfide bond reduction and oxidation, 
and form transient mixed disulfide bonds with the two
reductases. More recently, thioredoxin and proteins with 
thioredoxin-like domains (reviewed in [4]) have been
implicated in several seemingly unrelated processes: tran-
scription factor modulation (of NFkB [5], the glucocorti-
coid receptor [6], and AP-1 through Ref-1 [7]); protein
folding (by protein disulfide isomerase [8] and DsbA [9]);
cell growth stimulation (as a domain in the gonadotropic
hormones [10] and as an exported thioredoxin, summa-
rized in [11]); cell growth inhibition (by interferon-g [12]);
in pregnancy (as a component of the early pregnancy
factor [13]); and in reduction of sulfenic and sulfinic acids
[14]. This broad specificity for thioredoxin and related
proteins has made it difficult to distinguish true physiolog-
ical partners for the protein from in vitro artifacts.
Two functional aspects of thioredoxin and related proteins
have recently received considerable attention. The first
concerns the means by which the redox potential is modu-
lated among the thioredoxin family of proteins. All thio-
redoxin-like proteins contain the active-site sequence
CXXC, and all apparently have depressed pKas for the
first cysteine in this sequence. For example, Cys32 in
human thioredoxin has an estimated pKa of 6.3 [15], and
Cys30 of DsbA, a disulfide oxidoreductase found in the
E. coli periplasm, has an estimated pKa of 3.5 [16]. The
unperturbed pKa of cysteine is about 8.7. (Numbering
used throughout is for human thioredoxin, starting from
the N-terminal methionine. Residues from the second
monomer of the thioredoxin homodimer are designated
with a prime (′), as in Cys73′.) The oxidative power among
these proteins is also variable, with thioredoxin being
more reducing than, for example DsbA. This factor relates
to function: thioredoxin helps maintain the reducing envi-
ronment of the E. coli cytosol, and DsbA the oxidizing
environment of the E. coli periplasm. Considerable effort
has recently been concentrated on understanding how the
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oxidative power of proteins in the thioredoxin family is
related to the reduced pKa of the first active-site cysteine,
and how the active-site environment modulates this pKa.
Approaches to these questions have included structural
[1,4], mutagenic [17,18], and modeling [19,20] studies,
and it is clear that both the cysteine pKa and the thio-
redoxin redox potential can be modulated by simply alter-
ing the residues in the X positions of the CXXC
amino-acid segment. However, the mechanism by which
the cysteine pKa is lowered remains unclear.
A second area of recent interest is the role of thioredoxin
as an extracellular growth factor in mammalian tissues.
Thioredoxin has been identified as the growth factor
secreted by virus-transformed leukemic cell lines
(referred to as adult T-cell derived leukemic factor or
ADF [21]), and is overexpressed in certain tumors and
tumor-derived cell lines [22–24]. The protein can be
secreted by cells [25–27] through an unusual leaderless
pathway [26]. Exogenously added human thioredoxin,
but not E. coli thioredoxin, is capable of stimulating
growth in a number of solid-tumor derived cell lines in
the absence of serum, conditions under which many
growth factors are incapable of working [11]. These find-
ings suggest that thioredoxin may function as a growth
factor for some forms of cancer. Although the mechanism
by which thioredoxin works in this regard is not yet clear,
it requires a functional thioredoxin active site [28], but
apparently does not require a stable thioredoxin–receptor
complex to be formed [11]. It is possible that extracellular
thioredoxin functions by enhancing the activity of
endogenously produced growth factors [11]. Cancer cells
transfected with wild-type thioredoxin show increased
anchorage-independent growth while a redox-inactive
mutant thioredoxin acts in a dominant-negative manner
to inhibit anchorage-independent growth (GP and JRG,
unpublished observations). A series of imidazolyl disul-
fide containing compounds that inhibit thioredoxin and
thioredoxin reductase can also prevent cell-growth stimu-
lation by thioredoxin in cell culture [29,30]. Thus, human
thioredoxin may provide an excellent target for rational
drug design.
Extensive structural data exist for thioredoxin. The crystal
structures of oxidized thioredoxin from E. coli [31,32] and
the cyanobacteria Anabaena [33] have been determined, as
well as the oxidized and reduced solution structures of
thioredoxin from E. coli [34] and a mutated form of the
human protein [35]. The NMR structure of the same
mutated human thioredoxin has also been determined in a
disulfide-linked complex with a peptide from the tran-
scription factor NFkB [36]. The human protein used in
the NMR studies is mutated at four sites: three non-
active-site surface cysteines are replaced by alanine
(Cys62→Ala, Cys69→Ala, Cys73→Ala), and Met74 by
threonine (Met74→Thr). The cysteines were changed to
eliminate difficulties with the formation of interchain
disulfide bonds [35,37], and the Met74→Thr mutation is
apparently a cloning artifact [21,23,38–40]. In all of these
structures thioredoxin is a compact globular protein with a
five-stranded b sheet surrounded by four a helices. The
conserved active site amino acids Trp–Cys–Gly–Pro–Cys
link the second b strand to the second a helix, and form
the first turn of the second helix. Differences in the posi-
tion and hydrogen bonding of these amino acids in the
human and E. coli structures has contributed to the uncer-
tainty as to which components of the thioredoxin active
site are necessary for a reduced cysteine pKa [35,41].
Here we report the crystal structure of reduced wild-type
human thioredoxin (Trx-red), the first such crystal struc-
ture for any thioredoxin, and only the second for any
protein in the thioredoxin family [42]. We also report 
the structure of the oxidized human protein (Trx-ox), 
and the structures of two mutant forms of the protein
(Cys73→Ser, C73S; Cys32→Ser/Cys35→Ser, C32S/C35S)
designed to probe the role of disulfide bond formation in
thioredoxin catalytic activity and oligomerization. In all of
these structures an unexpected dimeric form of human
thioredoxin was revealed, as well as a redox-dependent
conformational change in the active site and an unusual
thiol–thiol hydrogen bond that provides an explanation




Crystals of wild-type human thioredoxin were obtained
from a 50% 2-methyl-2,4-pentanediol (MPD) solution
buffered at pH 3.8, and diffracted beyond 1.7 Å nominal
resolution. The reductant dithiothreitol (DDT; 1–10 mM)
was required for crystal formation; the crystals used for
data measurement were grown in the presence of 5 mM
DTT. The structure was determined by molecular
replacement using the NMR structure of the Met74→Thr
variant of human thioredoxin as a starting model (PDB
entry 3TRX [43]). The higher resolution human quadru-
ple mutant (hQM-Trx) NMR model described in the
Introduction was not available at the outset of the present
study, but has been used in the comparisons below. The
single and quadruple mutant thioredoxin NMR models
are not substantially different [35]. Residue 74 was left as
a threonine in the initial search model, and provided a
convenient internal check on the progress of the molecu-
lar replacement structure determination.
Trx-red was refined to a crystallographic R factor of 0.21 at
1.7 Å resolution (Table 1). The crystal structure was very
similar to the solution structure of the quadruple mutant
protein except for two striking features: the active-site loop
containing Cys32 and Cys35 had shifted by approximately
4 Å and the protein crystallized as a disulfide-linked dimer
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connected through Cys73 from each monomer. The two
active-site cysteines were in the reduced form, as shown in
the 2Fo–Fc electron density map in Figure 1a. The posi-
tions for all 105 amino acids are clear in the current elec-
tron-density map except for the Ca and Cb atoms of
Trp31, which are apparently disordered (this is not the case
for the oxidized structure, discussed below), and the N-ter-
minal methionine, which is either poorly ordered in the
crystal (it makes only one intramolecular and no intermol-
ecular contacts), or not present in all copies of the protein.
The N-terminal methionine may be cleaved from human
thioredoxin in vivo [3,44,45]. The side chains of Asp20,
His43 and Ser90 occupy two positions in the crystal and
have been refined as such. 
Crystals of Trx-ox, C32S/C35S, and C73S were isomor-
phous with crystals of Trx-red, and the structures of these
proteins were determined through manual rebuilding of
the Trx-red structure into difference, unbiased omit
(where phase bias toward the atoms to be fitted has been
removed), and 2Fo–Fc electron-density maps, alternated
with cycles of least squares refinement. Crystals of oxidized
thioredoxin were obtained by allowing the crystals of the
reduced protein to slowly oxidize over a two month period
(we have been unable to obtain crystals in the absence of
reductant). Numerous local changes occurred in the protein
on oxidation resulting in reduced diffraction and a lower
quality model than for the other three structures (discussed
below). The C32S/C35S and C73S structures were essen-
tially identical to Trx-red, except in the active-site and
dimer-interface regions. All cysteines not involved in disul-
fide bonds appeared fully reduced in all four structures, as
judged by Fo–Fc and omit electron-density maps, and tem-
perature factors for the sulfhydryls were similar to those for
nearby atoms. Maintaining reduced cysteines was aided by
relatively fast experimental parameters: crystal growth and
data measurement were completed in less than a week for
each of the Trx-red, C73S, and C32S/C35S structure deter-
minations. Difference electron-density maps between Trx-
red and each of Trx-ox, C32S/C35S, and C73S are shown in
Figures 1 and 2.
Dimeric human thioredoxin
Surprisingly, thioredoxin is dimeric in all four structures
determined in the present work. The crystals contain a
monomer in the asymmetric unit and the two monomers
of each dimer are related through the crystallographic
twofold rotation axis. Thioredoxin is thought to function
as a monomer in redox reactions. An inactive dimeric form
of human thioredoxin has previously been noted, leading
to the suggestion that dimer formation may function in a
regulatory capacity [37,46]. The dimer interface of Trx-
red consists of three components: an approximately
1100 Å2 (550 Å2 per monomer) largely hydrophobic patch;
five hydrogen bonds; and the Cys73–Cys73′ disulfide
bond. Oligomeric organization in crystallized proteins is
not uncommon (see, for example, the packing in E. coli
thioredoxin crystals [31]). Therefore a logical question to
ask at this stage is whether the dimer found in these crys-
tals represents a normal state for the protein. Discussed
below are several lines of evidence that suggest the
answer to this question is yes.
Electron density for the Cys73–Cys73′ disulfide bond is
shown in Figure 2a, and the thioredoxin dimer interface is
shown in Figures 3–5. The disulfide bond lies directly on
the dimer twofold axis, on one side of a short, two-
stranded b sheet comprising residues 72–74 from each
monomer, and is solvent exposed (Fig. 3,4b). The bond is
apparently quite stable in the dimer as it occurs despite
the presence of 5 mM DTT in the crystallization drop, a
concentration sufficient to keep the active-site sulfhydryls
in the reduced state. The reason for this stability is not
clear but it is probably due in part to the perfect orienta-
tion for disulfide-bond formation of the two sulfhydryls in
the dimer, and the sterically restricted space for the two
groups in the dimer. 
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Table 1
Data collection and refinement parameters.
Crystal Trx-red Trx-ox C32S/ C73S
C35S
Space group C2 C2 C2 C2
a (Å) 67.9 67.8 67.8 67.8
b 26.5 26.4 26.4 26.3
c 51.7 51.8 51.6 51.5
b (°) 95.2 94.9 95.1 95.0
Data collection
Resolution (Å) 15–1.7 15–2.1 15–1.8 7–1.65
Total reflections 19 412 8894 23 947 22 700
Unique reflections 9477 4440 7917 9449
Completeness (%)
Overall 92 80 91 85
Outermost data shell 78 71 77 69
R-sym 0.047 0.049 0.044 0.064
Mean I/s(I)
Overall 44.9 40.4 52.0 28.8
Outermost data shell 7.0 12.7 7.9 4.4
R-iso – 0.20 0.14 0.13
Refinement
R-cryst 0.21 0.22 0.21 0.21
R-free 0.24 0.33 0.26 0.24
Rms deviation in:
Bond lengths (Å) 0.015 0.016 0.016 0.016
Bond angles (°) 2.8 2.8 2.7 2.6
Number of 
solvent molecules 45 36 49 58
Average B factor 17 19 18 20
Trx-red, wild-type thioredoxin with reduced sulfhydryls in the active site;
Trx-ox, wild-type thioredoxin with oxidized sulfhydryls in the active site;
C73S, mutated thioredoxin with Cys73 replaced by serine;
C32S/C35S, doubly mutated thioredoxin with Cys32 and Cys35
changed to serine; R-sym, R-factor for symmetry related intensities;
R-iso, R-factor between Trx-red amplitudes and amplitudes from the
other crystals; R-cryst, crystallographic R-factor; R-free, R-factor for a
randomly selected 10% of reflections not included in the refinement.
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Figure 1
Stereoviews of active site electron density
(Trx-red) and difference electron density
(C32S/C35S and Trx-ox). (a) 2Fo–Fc
electron-density map for Cys32 and Cys35 in
the Trx-red structure (contoured at 1.0s
above the mean value for the map). 
(b) Difference electron density map between
Trx-red and C32S/C35S, showing Cys32 and
Cys35. Only positive electron density is
shown (contoured at 2.7s). (c) Difference
electron density map between Trx-red and 
Trx-ox, showing Cys32 and Cys35. Positive
electron density contoured at 2.7s is shown.
(d) Same map as in (c), showing negative
electron density contoured at 2.7s. 
(Figure produced with FRODO [71,72].)
The dimer interface is composed of 24 amino acids (12
from each monomer, Figs 4,6), and covers about 10% of
the 5750 Å2 solvent-accessible surface of the monomer.
The majority of the contacts between monomers are
hydrophobic. Two hydrophobic patches, consisting mostly
of residues Trp31, Val59, Ala66, and Met74 from each
monomer, fit together to completely bury all eight side
chains. The resulting interface contains no intervening
solvent molecules, and is sufficiently closely packed that
no gaps large enough to accommodate a water molecule
are present. However, a small cavity does occur in the
interface between Trp31 from each monomer. This cavity
allows the two tryptophans to move toward one another
upon disulfide-bond formation in the active site (dis-
cussed below). Four groups which can form hydrogen
bonds, the carbonyl of Val59 and the nitrogen of the
Trp31 indole ring from each monomer, are buried and left
unsatisfied in the dimer.
Five hydrogen bonds are formed in the dimer interface.
Two of these result from the short interfacial antiparallel
b sheet: the carbonyl of Lys72 from each monomer hydro-
gen bonds to the nitrogen of Met74 on the opposite
monomer (2.8 Å). Two more result from the side chains of
Ser67 hydrogen bonding to the carbonyls of Trp31 in the
opposite monomers (3.0 Å). The fifth occurs between the
side chains of Asp60 from each monomer (3.2 Å). Such a
hydrogen bond, which requires a shared proton between
two carboxylates, is common at the crystallization pH of
3.8, but to occur at neutral pH it would require a pKa ele-
vated above the normal value of about 3.9. Whether this
hydrogen bond exists at neutral pH is not yet known, but
occurrences of appropriately elevated pKas for aspartate are
well documented (see, for example, [47–49]). One factor
which could serve to elevate the pKa of Asp60 in dimeric
thioredoxin is its proximity to Asp58 (Fig. 5a), which is
more solvent exposed and likely to have a lower pKa than
Asp60. Alternatively, Asp60 and Asp60′ might swing away
from one another in the anionic state, as they lie on the
edge of the dimer interface (Fig. 3b). In oxidized thio-
redoxin, the Asp60–Asp60′ hydrogen bond is replaced with
hydrogen bonds to Trp31 and Trp31′ (discussed below). 
The residues in the dimer interface are poorly conserved
among thioredoxins from 39 widely divergent species
[33], but highly conserved among eight vertebrate species
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Figure 2
Stereoviews of electron density for Cys73
and Ser73. (a) 2Fo–Fc electron density map
for the C73–C73′ disulfide bond in Trx-red
(contoured at 1.0s above the mean value for
the map). (b) Difference electron density map
between Trx-red and C73S for residue 73.
Only positive electron density is shown
(contoured at 2.7s). (Figure produced with
FRODO [71,72].)
(Fig. 6). Overall, vertebrate thioredoxins are 62% identi-
cal, and 10 out of 12 amino acids in the dimer interface
are invariant (83%). The two variable residues are Gln63
and Ser67. Gln63 forms van der Waals contacts with
Trp31 and Thr30 of the opposite monomer, contacts
which could still form in rabbit thioredoxin, in which
residue 63 is a lysine (the amino group of the lysine would
be solvent accessible in the rabbit dimer, as the amide of
the Gln63 is in the human dimer). The change of Ser67 to
alanine, which occurs in thioredoxins from several
species, would result in the loss of a hydrogen bond in the
dimer interface, however the exposed hydrogen bonding
partner (carbonyl 31) would be solvent accessible. The
conservation of the dimer interface amino acids suggests
dimeric thioredoxin may be a recent occurrence, possibly
evolving in response to the specific needs of higher
animals, or to spread redox functions to new (extracellu-
lar?) compartments. 
C73S
To begin investigating the features necessary for thiore-
doxin dimer formation, we determined the structure of the
C73S mutant thioredoxin. This protein is fully functional
in redox reactions ([37,50] and Gasdaska et al., unpub-
lished data), fully stimulates cell growth (Gasdaska et al.,
unpublished data), shows a reduction in oxidation-related
inactivation ([37], Gasdaska et al., unpublished data), and
is inactive as a component of the early pregnancy factor
[50]. C73S crystallized under conditions nearly identical to
those for the wild-type crystals, but grew more slowly,
possibly due to a higher dimerization dissociation constant
(discussed below). 
Despite the loss of the dimer interface disulfide bond,
C73S is dimeric in the crystal and is nearly identical to the
wild-type protein except for a few small changes in the
dimer interface. The introduced serines at position 73 are
in a conformation very similar to that for the cysteines of
the wild-type protein, and are connected through a hydro-
gen bond (3.2 Å, Fig. 5b). The dimer interface appears to
have relaxed slightly in the mutant protein, especially near
Trp31 where both main-chain and side-chain atoms have
shifted by about 0.5 Å. This shift enlarged the small cavity
between Trp31 from each monomer, allowing a poorly
ordered water molecule into the dimer interface (Fig. 5b).
This water lies on the crystallographic twofold axis and
has been refined with an occupancy of 0.5 (B=28 Å2). A
similar shift in Trp31, but in the opposite direction, also
occurs upon disulfide-bond formation in the active site
(discussed below).
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Figure 3
Ribbon drawing of the Trx dimer. (a) A view
parallel to the twofold rotation axis; (b) view is
perpendicular to the twofold axis. Ball-and-
stick representations for residues Cys32,
Cys35, and Cys73 are shown in (a), and
Asp60 and Cys73 in (b). (Figure drawn with
MOLSCRIPT [75].) 
The similarity in the structures of the wild-type and C73S
mutant proteins suggests that much of the thioredoxin
dimerization energy is provided by the non-covalent inter-
actions in the dimer interface, and does not simply
depend on disulfide-bond formation.
Dimer formation in solution
As the data above suggest that the human thioredoxin
dimer may play a physiological role, the conditions 
under which such a dimer can form is of interest. Some
preliminary conclusions relating to this are discussed in 
this section.
It is clear that human thioredoxin can form covalently-
linked dimers in solution [51], especially in the presence
of a strong oxidant [37] or when stored at the moderately
high concentration of 125 mM [11]. Covalently-linked
dimer formation is greatly reduced or eliminated, depend-
ing on solution conditions, for the mutant thioredoxin
C73S, which eliminates the dimer interface disulfide bond
found in the present work ([37,50] and Gasdaska et al.,
unpublished data). In our hands, wild-type thioredoxin
stored for approximately two months at a concentration of
1 mM, pH 3.8, and 4°C, was almost entirely in the form of
covalently-linked dimers, as judged by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in
the absence of reductant, although a small percentage of
monomeric and multimeric thioredoxin was also present
(data not shown). The dimeric and multimeric bands dis-
appear upon addition of fresh reductant. In contrast, C73S
stored under similar conditions remained largely free of
covalent dimers, although a small percentage of dimeric
and multimeric thioredoxin was present (data not shown).
It should be noted, however, that fresh reductant was
necessary to obtain crystals of the wild-type protein.
The concentration dependence of dimer formation has
not yet been fully characterized. Preliminary data for
dimer formation of the C73S protein as estimated by dif-
ference UV spectroscopy suggest a dissociation constant
of approximately 30 mM at pH 4.0, and a somewhat
higher one at pH 7.5 where the charge repulsion between
Asp60 from each monomer is likely to be greater (data not
shown). The wild-type protein, with the potential for
disulfide-bond formation across the dimer interface,
might have a considerably lower dissociation constant.
Thioredoxin concentrations in bovine tissue have been
estimated to be 1 to 10 mM [52], but may be considerably
higher in specific tissues where thioredoxin has been
induced to higher levels of expression [22–24]. This sug-
gests that thioredoxin concentrations may rise in certain
tissues to a level where dimeric thioredoxin is apparently
the favored form for the protein, and thus could play a
regulatory role in thioredoxin function. Also, thioredoxin
may pass through an oxidizing environment during
export, and, under sufficiently high thioredoxin concen-
trations, dimer formation could protect the active site
from oxidation. 
Dimer formation was apparently not detected in the
NMR structure determination, despite the use of 1.2 mM
thioredoxin in the study [35]. A possible explanation is
the presence of a threonine at amino acid 74, rather than
a methionine as in the wild-type protein we used. Met74
is completely buried and tightly packed in the dimer
interface (Fig. 5).
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Figure 4
Space-filling model of thioredoxin. (a) Trx-red monomer with residues
that make interchain contacts labeled and colored by atom type:
carbon (white), oxygen (red), nitrogen (blue), and sulfur (yellow).
(b) Trx-red dimer highlighting the positions of Cys32, Cys35, and the
Cys73–Cys73′ disulfide bond. Cys32 and Cys35 are largely inacces-
sible in dimeric thioredoxin. (Figure produced with INSIGHT II [69].)
Reduced active site
Despite the wealth of data concerning thioredoxin, the
mechanism by which the enzyme catalyzes disulfide
exchange remains unclear [1]. Both the E. coli and
human proteins display a depressed pKa for Cys32
(thought to be necessary for increasing the nucleo-
philicity of the thiolate group) and an elevated pKa for 
Cys35 [15,48,53]. Several possible mechanisms have
been suggested for the reduced Cys32 pKa, including
stabilization of the anionic form of Cys32 through hydro-
gen bonding between Cys32 and the amide of Cys35
[35], stabilization through interaction with the dipole of
a helix 2 [19,54], and stabilization through hydrogen
bonding to the Cys35 thiol [41]. Differences in the
details of the human and E. coli thioredoxin NMR and
X-ray structures have contributed to the uncertainty
surrounding this question.
The present structures favor the model suggested by
Dyson and co-workers [41] for the reduced pKa of Cys32
in E. coli thioredoxin. In Trx-red, the Cys32 and Cys35
sulfhydryls are optimally aligned for hydrogen-bond for-
mation, with Cys35 as the proton donor, and Cys32 as the
acceptor (Fig. 7a). The distance between the two
sulfhydryls is 3.9 Å, and the angles formed by Cys35Cb–
Cys35Sg–Cys32Sg and by Cys35Sg–Cys32Sg–Cys32Cb
are 105° and 70°, respectively. This arrangement is nearly
identical to that for a similar hydrogen bond found in the
crystal structure of L-cysteine, as determined by neutron
diffraction [55]. In that structure, the corresponding dis-
tances and angles were 3.85 Å, 95.9°, and 69.8°, respec-
tively. This hydrogen bond also occurs in the C73S
structure, despite a change in the conformation of residues
Ala29–Cys32 (discussed below). The pKa of Cys32 is prob-
ably depressed as a consequence of this hydrogen bond. 
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Figure 5
Stereoview of the thioredoxin dimer interface.
(a) Trx-red viewed down the crystallographic
twofold rotation axis. All twelve residues which
make interchain contact are shown, as well as
Asp58. (Labels for Val59, Ala66 and Lys72
are not included.) One monomer is shown in
black, the other is outlined, and the
Cys73–Cys73′ disulfide connection is in gray.
Atom types are distinguished by circles of
differing size (C=O<N<S), and shading
(oxygen and sulfur are gray). Hydrogen bonds
are indicated by dashed lines. (b) C73S (thick
lines) superimposed with Trx-ox (thin lines),
displaying the shifts in Trp31 and Asp60 that
occur upon removal of the dimer interface
disulfide bond or formation of a disulfide bond
in the active site. Also shown is a water
molecule that fills the gap between Trp31 and
Trp31′ in C73S, represented as an isolated
filled circle. (Figure produced with the
program MOLSCRIPT [75].)
The amide nitrogen of Cys35, which is hydrogen bonded
to Cys32 in the NMR structure of hQM-Trx, is too far
from the Cys32 sulfur for hydrogen bonding in either Trx-
red or C73S (4.6 Å in both structures), although this hydro-
gen bond does occur in the oxidized protein (discussed
below). The dipole of a helix 2 may also contribute to the
reduced Cys32 pKa. This dipole is pointed in the correct
direction for stabilization of the Cys32 thiolate anion, but
the Cys32 sulfhydryl is located on the edge of the helix
(Fig. 7a) and therefore somewhat offset from the optimal
alignment for stabilization. Thus, the major reason for 
the depressed Cys32 pKa is probably the stabilization 
of the thiolate anion through hydrogen bonding to the 
Cys35 sulfhydryl, possibly with a small additional effect
contributed by the dipole of a helix 2.
The basis for the increased pKa of Cys35 is less contro-
versial. Cys35 is almost completely buried in the present
crystal structures, which disfavors deprotonation of the
sulfhydryl. The depressed pKa of Cys32 would also serve
to elevate the pKa of Cys35, as deprotonation of Cys32
would place a negative charge next to Cys35. The place-
ment of Cys35 is due in part to a previously undetected
hydrogen bond between the Cys35 sulfur and the amide
nitrogen of Ala29 (3.7 Å in both Trx-red and C73S). These
groups are perfectly aligned and at an acceptable distance
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Figure 6
Amino acid sequence alignment for vertebrate
thioredoxins. Shown are the sequences for
human [21,23], monkey [76], calf thymus [3],
sheep [77], rabbit [44], mouse [21], rat [78],
and chicken [79] thioredoxins. Methionine is
shown in the first position, but is probably
removed in vivo in vertebrate cells [3,44,45].
Invariant amino acids (63%) are shown in bold
type, and the twelve amino acids of the dimer
interface, ten of which are invariant (83%), are
indicated with an asterisk. 
Figure 7
Stereoviews of (a) reduced and (b) oxidized
human thioredoxin active sites. Atom types are
distinguished by circles of differing size
(C=O<N<S), and shading (oxygen and sulfur
are in gray). Hydrogen bonds are indicated by
dashed lines. (Figure produced with the
program MOLSCRIPT [75].)
for hydrogen-bond formation [56]. The position of Cys35
is further restricted by its inclusion in a helix 2, and
through numerous van der Waals contacts.
The conformation of the thioredoxin active site for the
wild type human protein determined in the present study
is very close to that found in the E. coli protein, especially
with respect to the E. coli X-ray structure. In contrast, the
active site in the hQM-Trx NMR structure is quite differ-
ent than that of the present work. These differences may
be due to the mutations in and near the thioredoxin active
site. A detailed comparison of the known thioredoxin
structures is presented in a later section.
C32S/C35S
As the placement of the active-site loop in the present
structure was considerably different from that for the NMR
structure, and as the placement of this loop is likely to be
critical for thioredoxin function, we sought to further char-
acterize it through the mutant protein C32S/C35S. This
protein is inactive in catalysis and cell-growth stimulation,
but is a competitive inhibitor of thioredoxin reductase, sug-
gesting that the binding surface of the mutated protein is
unimpaired [28]. Crystals of C32S/C35S were obtained
under the same conditions as for the wild-type protein, and
were isomorphous with those of the wild type. The differ-
ence electron density map calculated from the Trx-red and
C32S/C35S diffraction data was largely flat except in the
active site, where two large peaks corresponding to the
sulfur atoms of Cys32 and Cys35 were found, as well as
smaller peaks near neighboring residues (Fig. 1b). 
Model building and refinement resulted in a structure for
the mutant protein that was nearly identical to that of
wild-type protein, except in the active site. Shifts in
active-site residues Ala29–Ser35 in the mutant move the
hydroxyl of Ser32 into van der Waals contact with the
hydroxyl of Ser35 (3.4 Å), and possibly also lead to hydro-
gen-bond formation between the Ser32 hydroxyl and the
amide nitrogen of Ser35 (3.3 Å). The side chain of Trp31
occupies a new position about 1.3 Å away from its position
in Trx-red. Small shifts in nearby residues accompany
those of Ala29–Ser35 allowing appropriate van der Waals
contacts to be maintained. For example, Met74 appears to
track the position of Trp31 by changing the conformation
of its side chain. 
The observed active-site conformation for C32S/C35S is
very similar to that of Trx-ox (discussed below), suggest-
ing that the conformational change observed upon oxida-
tion occurs simply by allowing Cys32 and Cys35 to move
closer together. For example, the hydrogen bond formed
between the Ser35 amide and the Ser32 hydroxyl is very
similar to that formed by the amide and the sulfur of
Cys32 in Trx-ox. Most interesting in this regard is the
position and degree of order observed for Trp31, which is
partially disordered in Trx-red and C73S, but fairly well
ordered in C32S/C35S and Trx-ox. This suggests that
Ala29–Cys32 settle into a single conformation simply by
removing the steric conflict between the sulfhydryls of
Cys32 and Cys35, rather than through formation of a disul-
fide bond across this span of amino acids. It is possible
that the resemblance of C32S/C35S to the oxidized wild-
type protein contributes to its ability to act as a competi-
tive inhibitor of thioredoxin reductase [28].
There is also a change in the hydrogen bonding of the
dimer interface in C32S/C35S. The hydrogen bond
between Glu58 and Asp60 (Fig. 5a) has been replaced by
hydrogen bonds from each residue to an ordered water
molecule which, in turn, forms two additional hydrogen
bonds to the amide nitrogen and side-chain hydr-
oxyl of Thr30 (not shown). The four hydrogen bonds 
formed by this water molecule range from 2.7 to 3.0 Å in 
length. In the oxidized structure, Asp60 hydrogen bonds
to Trp31 (see below). 
Oxidized thioredoxin
We pursued the structure of oxidized thioredoxin in order
to assess changes in the active site upon disulfide-bond
formation. The approach taken, as reductant was required
for crystal formation, was to allow spontaneous oxidation
to occur in crystals of reduced thioredoxin by storing the
crystals in solution without replenishing the reductant
DTT. Such crystals diffracted beyond 2.0 Å resolution
despite a doubling of the mosaic spread (to 1.0°), and a
slight change in cell constants (Table 1). A comparison of
amplitudes from an oxidized crystal and Trx-red yielded a
merging R factor of 0.20, higher than the values obtained
with the two mutated protein crystals (Table 1).
The difference electron density map between Trx-red
and the oxidized crystal revealed numerous peaks
(Fig. 1c,d), the most prominent of which was between the
Cys32 and Cys35 sulfhydryls of the Trx-red model
(Fig. 1d), indicating that Cys32 and Cys35 were disulfide
linked in Trx-ox. Smaller difference peaks in the active
site indicated a conformational change similar to that
which occurred in C32S/C35S. A model for the oxidized
protein was thus built and refined with this disulfide bond
in place. The final electron-density map for this model
was of somewhat lower quality than that of the other struc-
tures. Likewise, R-free for the structure, which provides
an unbiased comparison of the observed and modeled
structure factor amplitudes, was higher than expected for a
well refined structure. Therefore the Trx-ox model must
be regarded as less reliable than the other thioredoxin
models. That there are no major errors in the placement of
atoms in the final Trx-ox model was confirmed through
inspection of the Trx-red–Trx-ox difference electron
density map (Fig. 1), and the phase-bias-removed ‘omit’
electron density maps (see the Materials and methods
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section). It is unclear why R-free is high for these data, but
this may be related to the high mosaic spread of the oxi-
dized crystals, or possibly to an anisotropic disorder in the
crystal, as was recently described by Sheldrick and co-
workers for cytochrome c6 [57]. 
Numerous small differences occurred in the active site
and dimer interface of Trx-ox with respect to Trx-red, but
in general the structures were very similar (the rms devia-
tion in Ca positions was only 0.26 Å). To form the disul-
fide bond, Cys32 moved toward Cys35 through shifts in
Ala29–Cys35, much like that which occurred in the
C32S/C35S mutant structure. Cys35 moved slightly
toward Cys32 on forming the disulfide bond, which had a
bond length of 2.0 Å in the final model. The largest move-
ment was in the indole ring of Trp31, which shifted about
1 Å away from its position in Trx-red, and was accompa-
nied by a reorientation in the side-chain conformation of
Met74. The electron density for the main-chain atoms of
Trp31 was better defined in Trx-ox than in either Trx-red
or C73S, and of similar quality to that of C32S/C35S,
where a similar conformation for the residue is found.
However, the electron density for Cb of Cys35 was of
lesser quality in Trx-ox than in the other structures where
it was excellent (see Fig. 1a). The positions for these
groups are stabilized by a hydrogen bond between the
sulfur of Cys32 and the amide nitrogen of Cys35 (3.2 Å,
Fig. 7b). As mentioned above, this hydrogen bond is
absent in the reduced structure where the two groups lie
well apart (4.6 Å). This hydrogen bond also occurs in the
oxidized E. coli thioredoxin X-ray and NMR models, as
well as in the models of the oxidized and reduced
hQM-Trx, but not in the reduced E. coli NMR model. 
An interesting change also occurs in the dimer interface of
Trx-ox as compared with Trx-red. The Asp60–Asp60′
hydrogen bond of Trx-red (Fig. 5a) has been replaced by a
hydrogen bond between Asp60 and the indole nitrogen of
Trp31 in each monomer of Trx-ox (Fig. 5b). A similar
hydrogen bond occurs in the crystal structure of oxidized
E. coli thioredoxin. In contrast to our observation, the
NMR groups not only report this hydrogen bond to be
present in the oxidized human and E. coli proteins [34,35],
but also in the reduced proteins, although it should be
noted that the geometry for such hydrogen bonding is
poor in both the human model and in the low resolution
E. coli model [58], which is the only E. coli NMR model
available at present in the protein data bank.
Comparison of reduced, oxidized and mutant structures 
The four thioredoxin structures determined in the present
work have the same general structure, and all are dimers.
The rms deviation between Ca positions ranges from
0.13 Å (between C73S and Trx-red) to 0.33 Å (between
C73S and Trx-ox). The main differences among them
occur in active-site residues Ala29–Cys35, and in dimer
interface residues Lys72–Met74. The most pronounced
movement occurs at Trp31, which lies both in the active
site and in the dimer interface. Upon oxidation, Trp31
moves across the active site towards Met74 (Fig. 8a), and
across the dimer interface toward Trp31′ of the second
monomer (Fig. 5b). The distance between Trp31 and
Trp31′ (measured between side-chain atoms CZ2 from
each monomer) is 6.2, 5.6, 4.0 and 3.8 Å for the structures
C73S, Trx-red, Trx-ox, and C32S/C35S, respectively.
Thus, as Cys32 and Cys35 move closer together, so too do
Trp31 and Trp31′, eventually contacting one another in
the dimer interface. 
To accomplish this conformational change, residues
Ala29–Cys35 pivot about the sulfur of Cys35, which does
not change in position, resulting in a more closed active
site (Fig. 8a). The double mutant C32S/C35S undergoes a
similar conformational change to that of Trx-ox, suggest-
ing that the pivot motion about Cys35 in the wild-type
protein simply requires the occurrence of a reduction in
the distance between the two active-site sulfhydryls. Con-
tacts among residues in the dimer interface apparently
induce a partial closure of the active site, as removal of the
disulfide bond between Cys73 and Cys73′ in C73S causes
a slight relaxation in the dimer interface, allowing active-
site residues Ala29–Cys35 to pivot to a more open position
than found in Trx-red (Figs 5b,8a). Despite this shift, the
hydrogen bond between the active-site sulfhydryls
remains in place in the C73S structure (3.8 Å). 
Two additional consequences of oxidation and conforma-
tional change in the thioredoxin active site are the tighten-
ing of a helix 2, and the loss of a hydrogen bond to the
Cys35 sulfhydryl. The carbonyls of Cys32 and Gly33 
form well-aligned hydrogen bonds to the amide nitrogens
of Lys36 and Met37, respectively, in the first turn of
a helix 2 in the oxidized structure (3.2 and 2.9 Å, respec-
tively), but the first of these is lost (3.5 Å) and the second
weakened (3.2 Å) in the reduced structure. The shift in
the Cys32 and Gly33 carbonyls can be seen in Figure 8a.
In contrast, the hydrogen bond between the sulfhydryl of
Cys35 and the amide of Ala29 (3.7 Å apart in Trx-red) is
lost upon oxidation (4.2 Å apart in Trx-ox). This balancing
of hydrogen bonds may help to ensure the reversibility of
thioredoxin oxidation and reduction.
Comparison with other thioredoxin structures
All known structures of thioredoxin, whether determined
by NMR or X-ray diffraction techniques, have the same
general fold. Differences among the structures do exist,
however, especially in the exterior loops of the protein,
including that of the active site (Fig. 8b). The thioredoxin
fold consists of a core five-stranded b sheet flanked by four
a helices (Fig. 3). The active-site peptide Ala29–Lys36
includes the end of b strand 2, two to three linking amino
acids, and the beginning of a helix 2. The rms deviation in
Research Article Crystal structures of human thioredoxin Weichsel et al. 745
Ca positions between Trx-red and the average NMR
structure for reduced hQM-Trx is 1.2 Å, and the two struc-
tures are sufficiently similar to have allowed a structure
determination by molecular replacement (using the nearly
identical single mutant NMR structure).
Despite these similarities, the distribution of differences
between the two structures was decidedly non-random
(Fig. 9a). The largest differences occur in the active-site
peptide Ala29–Lys36, where deviations greater than 3 Å
occur. The smallest deviations are in the b sheet, which
displayed an rms deviation of 0.51 Å. Both the position
and conformation of the Cys32/Cys35-containing active-
site loop differs in Trx-red with respect to the same loop
in the hQM-Trx NMR structure. Conformational differ-
ences occur in residues Ala29 and Thr30, where c differs
by ~30°; in Ser28, where an additional hydrogen bond at
the end of b strand 2 occurs in the X-ray structure (2.9 Å);
and in a helix 2 (residues 33–47), where there is a notice-
able regularization in hydrogen bonding in Trx-red. The
altered conformation in these residues is coupled with
additional shifts in the amino acids they contact, including
residues 74–75, and 92–97.
We also compared the human and E. coli thioredoxin struc-
tures. To do so, we superimposed residues 23–48, and
52–93 (numbering corresponds to that of the human
sequence), as these residues were the least affected by
insertions and deletions. Unexpectedly, both the E. coli
reduced NMR structure (1.11 Å rms deviation) and the
E. coli oxidized X-ray structure (0.79 Å and 0.81 Å rms
deviation for monomer 1 and 2, respectively) were in better
agreement with Trx-red for these 68 residues than the
human NMR structure (1.19 Å rms deviation). This trend
was even more pronounced for the cysteine-containing
peptide that spans the active site: rms deviations were 1.08,
0.80, and 0.34 Å for the Ca positions of residues 28–38 for
the human NMR, the E. coli NMR, and the E. coli X-ray
structures, respectively, when fitted to the same residues
in Trx-red. Similar deviations resulted upon comparison of
the equivalent oxidized structures. Thus, despite having
only 27% sequence identity, the two X-ray structures are in
better agreement than any other pair of structures. Possibly
this is a reflection of the high resolution for the two X-ray
structures (~1.7 Å in both cases). It should be noted that
the low-resolution E. coli thioredoxin NMR structure [58]
was used in the comparison, as the high-resolution struc-
ture [34] is not yet available. Figure 8b shows the thiore-
doxin active site for three of the oxidized structures after
superposition of the b sheet regions of the proteins.
Several factors should be noted when comparing the X-ray
and NMR structures of the human thioredoxin active site.
In the X-ray structure the active site is blocked by dimer
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Figure 8
Stereoviews of the differences among the
thioredoxin active sites, after superposition.
(a) Residues Trp31–Cys35, Cys73–Pro75,
and Lys72′–Cys73′ (from the other monomer)
for C73S (blue), Trx-red (red), Trx-ox (green),
and C32S/C35S (pink). (b) Trp31–Lys36,
Val59–Asp60 and Cys73–Pro75 for the 
hQM-Trx (NMR, green), human Trx-ox (X-ray,
red) and E. coli (X-ray, blue). Cas from
residues 1–27 and 38–105 were used to
superimpose the oxidized hQM-Trx structure
with Trx-ox, and the Cas of the b sheet were
used to superimpose the E. coli crystal
structure with Trx-ox. (Figure produced with
the program MOLSCRIPT [75].)
formation, and Trp31 is completely buried in the dimer
interface. Such contacts could alter the conformation of the
Cys32–Cys35-containing loop. As discussed above and
shown in Figure 8a, this region of the protein displays con-
formational flexibility despite contacts in the dimer inter-
face. However, a comparison of the C73S and Trx-red
structures suggests additional conformations may exist.
That the active-site conformation we see for dimeric human
thioredoxin is likely to occur for the monomeric protein is
supported by its remarkable similarity to the active site of
the monomeric E. coli thioredoxin X-ray structure. These
structures retain nearly identical active sites despite low
sequence identity, dissimilar crystal forms, and dissimilar
intermolecular contacts near the active site in the crystal.
The protein used in the NMR study contains four altered
amino acids with respect to the wild-type protein (C62A,
C69A, C73A, M74T), is active, and has recently been
shown to form a mixed disulfide with a peptide from the
thioredoxin redox partner NFkB [36]. The conformation
seen in the crystal structure of the wild-type protein is not
among the 40 structure ensemble produced in the NMR
study (PDB entry 1trv). The reason for the differences in
the structures is not clear but may in part be due to the
M74T mutation, as Met74 makes numerous contacts with
Trp31 in the X-ray structure, and the M74T single mutant
NMR structure is very similar to that of the quadruple
mutant [34]. In the reduced X-ray structure, Val59, Ala29,
Trp31, and Cys32 all pack around the side chain of Met74,
while in the more open active site of the NMR structure,
only Val59 contacts Thr74 (Fig. 8b). It should also be
noted that the sulfurs of Cys32 and Cys35 are unusually
close together in the NMR structures (3.1 Å), and that all
of the mutation sites (Cys62, Cys69, Cys73, and Met74)
and some residues in contact with the mutation sites
(e.g. Ser7) display local conformational shifts (Fig. 9a).
We compared the rms deviations in the NMR structure
ensemble, which are related to conformational mobility in
solution, to the crystallographic temperature (B) factors,
which are related to conformational mobility in the crystal.
As shown in Figure 9b, the correspondence of the two
plots is fairly high. For example, the b sheet is the best
ordered portion in both structures. Two portions of the
plots that show greater than average deviations in the
NMR structure, but display temperature factors close to
the mean in the X-ray structure, are residues 29–39 and
66–75, both of which pass through the thioredoxin active
site and are in structurally different conformations in the
two structures. A possible explanation for this is that the
M74T mutation in the protein used in the NMR study led
to greater mobility in these residues through loss of con-
tacts to the methionine side chain, as described above.
Concluding remarks 
We have determined four crystal structures of human
thioredoxin, all of which were dimeric in the crystal and,
except for the C73S mutant, covalently linked through a
disulfide bond. Several factors suggest the thioredoxin
homodimer may play a physiological, possibly regulatory,
role. First, the residues that occupy the dimer interface are
more highly conserved than the rest of the protein among
vertebrate thioredoxins. Second, covalently linked dimers
are readily formed at thioredoxin concentrations above
125 mM, even in the presence of the reducing agent
DTT. Third, wild-type thioredoxin rapidly loses its bio-
logical activity (ability to stimulate cell growth) upon
storage in the absence of reducing agent (JR Gasdaska
et al., unpublished data), whereas the mutant C73S retains
its biological activity upon storage. Fourth, the dimeric
form of thioredoxin is not a substrate for thioredoxin
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Figure 9
Comparisons of the solution and crystal structures of reduced thioredox-
in. (a) Rms deviation between Ca atoms for Trx-red and the reduced
hQM-Trx NMR structure, after superposition. All Ca atoms were used
for superposition. (b) Plot of Ca temperature factors for Trx-red (Å2,
thick line), and Ca rms deviations among the 40 NMR structures
generated for the hQM-Trx (Å× 100, thin line). Regions of secondary
structure in the thioredoxin monomer are indicated by stippled boxes 
(b-sheet strands) and zigzags (a helices).
(a)
(b)
reductase. Fifth, Cys73 is required for thioredoxin to func-
tion as a part of the early pregnancy factor [50], one of
several newly discovered extracellular functions for the
protein. Experiments are under way to determine what
role, if any, dimer formation plays.
Insight into extracellular function might also be gained
through comparison of thioredoxins from different
species. Human and E. coli thioredoxins display remark-
ably similar structures, but do not function identically,
especially with respect to autocrine activity. Human
thioredoxin can stimulate a variety of tumor-derived cell
lines to grow in the absence of added serum, whereas
E. coli thioredoxin, at least for the breast cancer cell line
MCF-7 [11], cannot. E. coli thioredoxin can produce a
transient increase in DNA synthesis by human lymphoid
cells in the presence of serum [59], and so is not com-
pletely without extracellular activity. Both redox activity
and reduction by an extracellular thioredoxin reductase is
apparently required for thioredoxin growth stimulation
[28]; however both proteins can serve as substrates for
human thioredoxin reductase [60], and therefore their
reduced forms can presumably be regenerated at the cell
surface. The dimeric form of human thioredoxin is appar-
ently not required for growth stimulation as dimer forma-
tion blocks the active site, and the C73S mutant protein,
which is less prone to dimerization, is fully active (Gas-
daska et al., unpublished data). The surface amino acids of
E. coli and human thioredoxins are quite different away
from the active site and these differences are likely to be
responsible for the lack of autocrine activity in the E. coli
protein. It is possible that the E. coli protein does not bind
to one or more of the cell surface proteins necessary for
initiating the growth signal, and thus cannot reduce a key
signaling intermediate.
Biological implications 
Thioredoxin is a ubiquitous oxidoreductase implicated in
an increasingly large number of biological activities,
including regulation of transcription factors such as
NFkB, and autocrine growth stimulation in some
tumors. The four crystal structures of human thio-
redoxin reported here provide new insight into the
thioredoxin mechanism and reveal a previously
unknown dimeric form of the protein.
The physiological role, if any, of thioredoxin-dimer for-
mation remains unclear. Small amounts of thioredoxin
dimer have been detected in cells ([37]; G Powis, unpub-
lished observations). It is possible that oxidant-induced
dimer formation is a method of sensing oxidizing condi-
tions in the cell: dimer formation removes thioredoxin
from the redox cycle catalyzed by thioredoxin reductase,
as the dimer is not a substrate for this enzyme [37].
Dimerization of secreted thioredoxin in the relatively
oxidizing extracellular environment could be a way of
limiting the growth stimulating effects of thioredoxin: the
thioredoxin dimer does not stimulate cell proliferation
(JR Gasdaska et al., unpublished data).
The evidence reviewed previously that thioredoxin is
important for cell proliferation and cell transformation,
and the finding that some human cancers show greatly
increased thioredoxin gene expression [22,23], suggest
that thioredoxin could be a target for anti-cancer drug
development. X-ray crystallographic studies are under
way to aid in the design of such inhibitors. 
Materials and methods
Crystallization and diffraction measurement
Wild-type and mutant human thioredoxins were expressed and purified
as previously described ([11,28], Gasdaska et al., unpublished data).
Amicon 3k MCO filters were used to concentrate and equilibrate the
proteins with 10 mM sodium acetate buffer (pH 3.8) supplemented
with 5 mM DTT. Rhombohedral crystals were grown by the hanging
drop method from a solution containing 10 mM sodium acetate buffer
(pH 3.8), 25% (v/v) 2-methyl-2,4-pentanediol (MPD), 5 mM DTT, and
equilibrated at room temperature against the same solution with 
50% MPD. The initial protein concentrations in the crystallization drops
were 5, 4, and 6 mg ml–1 for wild-type, C32S/C35S, and C73S
proteins, respectively. Crystals of Trx-red measuring approximately
0.4×0.2×0.2 mm were obtained after three days by seeding small
(<0.05 mm) crystals into drops pre-equilibrated for approximately 2 h
against the precipitant solution. Such crystals diffracted beyond 1.7 Å
resolution, were stable in the X-ray beam for several days, and were
stable in the crystallization drop at room temperature for several
months. Crystals of Trx-ox were obtained by allowing crystals with
reduced active-site sulfhydryls to oxidize in the crystallization drop for
approximately two months by withholding the addition of fresh DTT.
The oxidized crystals displayed a twofold increase in mosaic spread,
but still diffracted beyond 2.0 Å resolution.
X-ray diffraction data were measured at room temperature using a
FAST area detector with graphite monochromated CuKa radiation gen-
erated from an Enraf-Nonius FR571 rotating anode. Each diffraction
image was recorded for 60–100 s while rotating the crystal through
0.15° in omega. Intensities were estimated using the programs
MADNES [61], PROCOR [62], and FBSCALE [63]. The crystal and
data collection results are summarized in Table 1. 
Although human thioredoxin was crystallized under conditions similar to
those for the E. coli protein [64] the crystals were not isomorphous
with those of E. coli thioredoxin. The presence of 1 mM Cu2+, an impor-
tant component in the E. coli thioredoxin crystallization, did not affect
formation of the human thioredoxin crystals. 
Structure determinations
The crystal structure of Trx-red was determined through molecular
replacement using the NMR human M74T mutant thioredoxin structure
as a starting model (using the average NMR structure, PDB entry 3TRX
[43]). Rotation and translation searches were carried out with X-PLOR
[65]. The rotation search, performed with data between 15 and 2.8 Å
and filtered with 20 steps of Patterson correlation refinement, resulted
in a single peak well above all other peaks that eventually proved to be
the correct solution. The translation search was restricted to the x/z
plane of the unit cell, which is all that is required in space group C2.
The best solution had a crystallographic residual (R-factor) of 0.52, a
correlation coefficient value of 0.31, and was statistically much better
than the next closest peak, which had a correlation coefficient of 0.20.
Rigid-body refinement reduced the R-factor slightly to 0.50. Simulated
annealing using a slow-cooling protocol for 3s data between 15 
and 2.8 Å was more successful and reduced the R-factor to 0.27.
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Parameter files distributed with X-PLOR version 3.1 were used
(param19x.pro and toph19x.pro). A 2Fo–Fc electron-density map calcu-
lated at this stage revealed clear electron density for most of the struc-
ture, but no density for the fragment between amino acids 30 and 36.
Cycles of refinement alternated with manual correction of the protein
model and the incremental inclusion of higher resolution data resulted
in improved electron density for the model, and revealed a new position
for residues 30–36. An intermolecular disulfide bond was also discov-
ered involving Cys73 and Cys73′ of the crystallographically twofold-
related monomer, as well as good density for Met74, which had been
left in the mutant form of the protein (threonine) to this stage. During
rebuilding, the side chains of Asp20, His43, and Ser90 were found to
occupy two conformations, and have been built and refined as such.
Statistics concerning the final 1.7 Å model can be found in Table 1.
Crystals of the mutant thioredoxins C73S and C32S/C35S were iso-
morphous with those of the wild-type protein, which allowed the Trx-red
model to be used as a starting model in the refinement of both struc-
tures. New positions were found for residues in the active site and
dimer interface, and modeled as such. Two conformations for Ser90
were included in the final refinement of the C73S mutant, and for
His43 in C32S/C35S.
A crystal of wild-type thioredoxin allowed to oxidize for two months
was used to collect diffraction data to a resolution of 2.1 Å (reductant
was required for crystallization). The oxidized crystals did not diffract
as well as the reduced crystals and had a doubling in the mosaic
spread (to 1.0°), but displayed acceptable agreement among symme-
try related reflections (Rsym=0.049). A difference electron density map
between Trx-red and these data revealed a strong positive peak
between the sulfur atoms of cysteines 32 and 35, confirming the pres-
ence of a disulfide bond between the two residues, and numerous
smaller peaks consistent with a conformational change in the active
site similar to that found for C32S/C35S. The structure was refined
using X-PLOR with a constrained distance for the active site disulfide
bond. The 2Fo–Fc electron-density maps were fully interpretable for
manual adjustment of the model, but were of somewhat lower quality
than those for the other three structures. Unbiased omit maps, where
atoms under consideration were omitted from the model and phase
bias removed by either simulated annealing with X-PLOR or refinement
with GPRLSA [66,67], were used in the positioning of all atoms. The
final Fo–Fc electron-density map was essentially flat above the noise
level, and no residual positive or negative peaks occurred at any of the
sulfur positions. The final model displayed excellent stereochemistry,
good agreement with the difference Fourier between Trx-red and 
Trx-ox, and an acceptable R-cryst (0.22). However R-free was higher
than expected for a well refined model (0.33). The reason for the high
R-free is unclear but is possibly related to an unmodeled disorder in
the crystal, which may also have given rise to the high mosaic spread
observed for these crystals. Although the difference between R-free
and R-cryst suggests overfitting of the model, all parameters released
during refinement resulted in a reduction of both R-free and R-cryst.
Only 36 water molecules were included in the final model, and 
the temperature factors for connected atoms were highly correlated
(correlation coefficient=0.94). A similar structure determination under
way in our laboratory with an inhibited form of the oxidized protein dis-
plays similar refinement statistics, suggesting that the problem is a
general component of the oxidized crystals (data not shown). That no
major errors occur in the Trx-ox model was confirmed through the use
of unbiased omit maps, as described above. However, because of the
high R-free, the Trx-ox model must be considered less accurate than
the other three Trx structures.
The Cys73–Cys73′ dimer interface disulfide bond lengths were not
constrained during refinement, resulting in slightly incorrect distances
between the bonded sulfurs (~2.3 Å in all three models). The Cys73
sulfur positions were manually shifted to yield more appropriate bond
lengths in the final models (2.0 Å). The new sulfur positions were in
good agreement with the electron density for these atoms (Fig. 2).
The positions for all amino acids were checked using ‘omit’ maps.
Model geometry was checked with PROCHECK [68] and all four
models had at least 92% of their amino acids in the most favorable
regions of a Ramachandran plot. Statistics concerning the geometry of
the final models are given in Table 1. Structures were superimposed
and rms deviations calculated using the programs INSIGHTII [69] and
X-PLOR [65]. The fractional accessibility of protein atoms to solvent
and the surface area of the dimer interface were calculated with the
program GRASP [70]. Model building was performed with FRODO
[71,72] and general crystallographic calculations performed with
CCP4 [73]. Sequence alignments were obtained with GCG [74].
Accession numbers
Coordinates have been deposited with the Protein Data Bank, and
have accession numbers 1ert (reduced thioredoxin); 1eru (oxidized
thioredoxin); 1erv (C73S mutant thioredoxin) and 1erw (C32S/C35S
mutant thioredoxin).
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